André Bachmann and his associates at the Secchia Center in Grand Rapids have been hard at work developing a new drug for cancer patients. It has the potential to be effective in treating neuroblastoma—a common form of childhood cancer.
The American Cancer Society lists neuroblastoma as the most prevalent cancer in infants. Bachmann’s research involves repurposing the drugs DFMO and TIR-199 to treat the deadly strain.
WKAR's Skyler Ashley spoke with Dr. Bachmann to gain insight into his research and learn more about the process of what it takes to get a drug on the market to treat cancer patients.
